A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response ...
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...
Mayo Clinic researchers say they have discovered that ovarian cancer cells can quickly activate a survival response after treatment with PARP inhibitors.
Targeted Oncology: For the community oncologist, the choice between niraparib and olaparib often comes down to the patient's molecular profile. In a pMMR/HRD-negative patient, what clinical markers ...
Scientists at Mayo Clinic have discovered that a drug originally developed for lung cancer could help make a common ovarian cancer treatment more effective. The research reveals why some ovarian ...
PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers. Niraparib approved for all-comers whose ...
A clinical-stage oncology company developing targeted therapies that exploit DNA damage response (DDR) vulnerabilities in ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Liu is a ...
The article by George et al entitled “Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms” (JCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results